Announced promising safety and positive biomarker data from Cohort 2 (5mg BID) of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients demonstrating dose dependent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback